Clinical Trial

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Study acronym: RemiSeven
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-28; most recent amendment 2026-05-19.
Trial Details
NCT Number NCT07222956
Lead Sponsor Moein Amin
Collaborators: Novartis Pharmaceuticals
Conditions Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Enrollment 20 participants
Start Date 2026-06-30
Primary Completion 2030-10-30 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-20